It is reasonable to propose that, in addition to T cells, NK cells participate in the clinical benefit of anti–PD-1/PD-L1 antibody therapy by directly killing tumor cells and/or recruiting T cells67. This evidence concerns the gene PDCD1 and neoplasm.